GeneOne Life Science, Inc. (KRX:011000)

South Korea flag South Korea · Delayed Price · Currency is KRW
638.00
-56.00 (-8.07%)
Last updated: Jun 22, 2026, 1:36 PM KST
Market Cap62.93B -77.9%
Revenue (ttm)17.12B -54.0%
Net Income-45.40B
EPS-532.28
Shares Out 90.67M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,984,920
Open666.00
Previous Close694.00
Day's Range604.00 - 725.00
52-Week Range617.00 - 2,785.00
Beta0.62
AnalystsSell
Price Targetn/a
Earnings DateAug 14, 2026

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1976
Employees 41
Stock Exchange Korea Stock Exchange
Ticker Symbol 011000
Full Company Profile

Financial Performance

In 2025, GeneOne Life Science's revenue was 23.04 billion, a decrease of -35.49% compared to the previous year's 35.72 billion. Losses were -51.85 billion, 6.83% more than in 2024.

Financial Statements